Follow the latest news about PreComb
2023
November
2023
PreComb announces collaboration with Numab
PreComb is pleased to announce a commercial collaboration with Numab Therapeutics to evaluate one of their exploratory T-Cell engagers with PreComb’s 3DTwin platform in one of the major cancer indications.
October
2023
PreComb listed in the top 20 of Europe's emerging cancer tech startups
Financial Times backed sifted listed PreComb under the most promising cancer tech startups in Europe.
July
2023
PreComb to present on the "Clinical implementation of functional precision medicine" at the Next gen organ-on-a-chip and Organoid workshop
Jens Kelm is presenting the latest advances and clinical implementation of PreComb’s 3DTwin technology platform at the CSEM workshop on August 24 in Zurich.
July
2023
PreComb enters clinical collaboration with the National Center for Tumor Diseases (NCT) Dresden
Hombrechtikon, July 19th, 2023
PreComb announced today the start of a clinical collaboration with Prof. Dr. Hanno Glimm and Dr. Claudia Ball from the Department for Translational Medical Oncology at NCT/UCC in Dresden. The collaboration aims to clinically validate PreComb’s 3DTwin® plattform across a broad range of solid tumor indications.
Read full press release.
March
2023
PreComb and the University Hospital Aachen enter into a strategic collaboration
Hombrechtikon, March 31st, 2023
PreComb today announced the start of a strategic collaboration with Prof. Dr. Lars Küpfer of the Institute of Systems medicine with Focus on Organ Interaction (ISM) at the Uniklinik RWTH Aachen, Germany.
“We are excited to work with PreComb to help finding effective cancer therapies,” said Prof. Dr. Lars Küpfer. “Access to experimental data from PreComb will significantly help us to improve our model-based analyses of cancer drug responses. A particular focus lies on translation of in vitro results to the in vivo situation in patients at truly physiological conditions.”
Read full press release.
March
2023
PreComb Therapeutics appoints Carl L. Liederman, Esq., to the Board of Directors
Hombrechtikon, March 7th, 2023
PreComb today announced the appointment of Carl L. Liederman to the PreComb Board of Directors, effective 7th of March 2023. Following the appointment of Carl Liederman, the Board will comprise four directors.
“We are pleased to welcome Carl Liederman to the PreComb Board”, said Peter Steiner, chairman of the board and chief operations officer at PreComb. “Carl’s deep experience in the life science space with a strong legal oversight will be invaluable to PreComb to grow our business and pursue our mission to help find and select cancer therapies that promote tumor regression.”
Read full press release.
February
2023
PreComb and mimiX biotherapeutics announce co-operation to reshape personalized cancer drug profiling
Hombrechtikon, February 21st, 2023
PreComb and mimiX Biotherapeutics join forces to fight cancer. The two companies announced they are partnering to accelerate the process of personalized cancer drug profiling leveraging the potential of both company’s proprietary technologies. PreComb is pioneering personalized cancer profiling with their proprietary 3DTwin® technology. By using mimiX’s Sound-Induced Morphogenesis (SIM) technology to make efficient use of patient’s tumor cells and accelerate in vitro tissue production, PreComb aims to provide more effective and targeted treatment options for patients. Efficient use of primary tumor tissue will enable frequent use of tumor biopsies for personalized drug testing unlocking a billion-dollar market.
Read full press release.
Jens M. Kelm, CEO
info@precomb.com
Communication & media:
roman.sojic@mimixbio.com
February
2023
PreComb Therapeutics appoints Dr. Helge Bastian as Strategic Advisor
Hombrechtikon, February 13th, 2023
PreComb is delighted to announce that Dr. Helge Bastian is joining the strategic advisory board of PreComb.
Dr. Bastian is a seasoned healthcare executive with over 30 years of international leadership experience and global business responsibilities at leading life science and healthcare corporations in Germany, Switzerland and the USA, including QIAGEN, SGS, Sigma-Aldrich, Indivumed, Thermo Fisher Scientific and M2GEN. He brings a wealth of expertise in the fields of life sciences, molecular diagnostics, clinical research, GMP-quality control testing, synthetic biology, personalized medicine and bio- and health informatics.
We are excited
to work with Helge to foster the paradigm shift in precision oncology.
Read full press release.
2022
November
2022
NZZ portrait PreComb
Hombrechtikon, November 23rd, 2022
As a finalist of the Swiss Technology Award, NZZ published a short company portrait of PreComb.
November
2022
3DTwin® analysis platform powered by IONOS SE
Hombrechtikon, November 8th, 2022
PreComb is part of the IONOS Startup Program to advance its novel 3DTwin® technology. The 3DTwin® technology is a fully automated drug sensitivity profiling solution that allows clinical and research institutions to generate comprehensive functional drug sensitivity profiles of patient-derived cancer cells.
October
2022
PreComb is in the final of Switzerlands leading technology prize
October 12th, 2022 – HOMBRECHTIKON, SWITZERLAND
Around fifty start-ups, established companies as well as educational and research institutions applied for the Swiss Technology Award 2022, nine have reached the final. We are proud to be among them. Now we are pitching for first place in the category ‘Start-ups (Rising Start)’ at the Swiss Innovation Forum 2022 on 23 November in Basel. We are looking forward to this unique experience and the exchange with other innovative minds during the conference day. Are you there too? Further information at www.swiss-technology-award.ch
The Swiss Technology Award is the most important award for innovation and technology transfer in Switzerland. Every year, the prize is awarded to the most outstanding technology-based innovations and developments in the categories ‘Inventors’, ‘Start-ups (Rising Stars)’ and ‘Innovation Leaders’. This year it will be awarded for the 34rd time.
October
2022
Personalised Oncology Platform PreComb Closes 1.3 Million CHF Pre-Series A Round
Investors in game-changing cancer treatment technology include LongeVC, Kinled and other biotech VCs
October 4th, 2022 – HOMBRECHTIKON, SWITZERLAND – PreComb Therapeutics announced today that it closed its 1.3m CHF Pre-Series A Round. Biotech and deep tech-focused venture capital firms LongeVC and Kinled, in addition to family offices and private investors, participated in the investment. PreComb is developing an evidence-based therapy prediction for cancer drug discovery and therapy guidance using its patented 3DTwin® technology.
August
2022
PreComb implements the first 3DTwin® Profiler at the University Hospital Zurich
Hombrechtikon, August 26th, 2022
PreComb Therapeutics started the implementation phase of its novel 3DTwin® Profiler at the University Hospital Zurich in the Department of Pathology and Molecular Pathology. The 3DTwin® Technology is a versatile drug sensitivity profiling technique that allows clinical and research institutions to generate comprehensive functional drug sensitivity profiles of patient-derived cancer cells.
February
2022
PreComb enters collaboration with the Innsbruck Medical University to advance immune-oncology personalized medicine
Hombrechtikon, February 21st, 2022
PreComb Therapeutics announced the start of a clinical collaboration with Dr. med. Arno Amann and Prof. Dr. med. Dominik Wolf of the Department of Internal Medicine V. Together, we will explore the potential of patient-derived microtumors to predict the response of immune-oncological drugs.
January
2022
PreComb and the University Hospital Zürich enter clinical collaboration
Hombrechtikon, January 25th, 2022
PreComb has entered into a clinical collaboration with the Department of Pathology and Molecular Pathology at the University Hospital Zürich (USZ) to develop novel prognostic models for cancer patients. Together with Prof. Dr. med. Chantal Pauli and Prof. Dr. med. Holger Moch, PreComb’s 3DTwin™ technology is clinically evaluated to provide clinitians with an automated platform to profile drugs and drug combinations directly on site.
January
2022
PreComb collaborates with KiTZ to evaluate 3DTwin™ technology in pediatric tumors
Hombrechtikon, January 13th, 2022
PreComb has entered into a research collaboration with the Hopp Children’s Cancer Center (KiTZ) the pediatric oncological institution of the German Cancer Research Center (DKFZ), the University Hospital Heidelberg and the University of Heidelberg. Our 3DTwin™ technology is being evaluated as part of the research collaboration with the “Functional Pediatric Precision Oncology” group of PD Dr. Ina Oehme and Prof. Dr. Olaf Witt. We are looking forward to a fruitful collaboration to foster cancer therapy for pediatric patients.
2021
November
2021
PreComb opens European branch in Germany
On November 22, PreComb has founded PreComb Germany GmbH as our European subsidiary in Lörrach, Germany.
November
2021
PreComb joins the Health Tech Cluster Switzerland
The Health Tech Cluster Switzerland is a network of service providers, research institutions and investors in the health technology sector.
October
2021
Impact Story about Jens Kelm published by Euresearch
Hombrechtikon, October 26th, 2021
Euresearch, a Swiss non-profit organization funded by the State Secretariat for Education, Research and Innovation SERI, has published an article about our CEO Jens Kelm and the impact of EU projects for funding of start ups like PreComb Therapeutics.
October
2021
PreComb Therapeutics and the Zurich University of Applied Sciences ZHAW have jointly developed AI-based image analysis algorithms for precision medicine
Hombrechtikon, October 8th, 2021
PreComb Therapeutics announces the successful completion of a joint master thesis with the Zurich University of Applied Sciences (ZHAW) Institute for Applied Simulation (IAS) under the supervision of Dr. Robert Vorburger who has extensive experience in knowledge engineering. The results gained in this master thesis by Thomas Wegmann are of great importance and will be incorporated into the novel 3DTwin technology for the prediction of therapy outcomes in cancer patients.
Read full press release.
Jens M. Kelm, CEO
info@precomb.com
ZHAW IAS Media contact
Dr. Rober Vorburger
office.ias@zhaw.ch
July
2021
PreComb Therapeutics and the Eastern Switzerland University of Applied Sciences enter strategic collaboration
Hombrechtikon, July 9th, 2021
PreComb Therapeutics today announced the start of a strategic collaboration with Prof. Dr. Agathe Koller of the Institute of Lab Automation and Mechatronics (ILT) at the Eastern Switzerland University of Applied Sciences (OST). Together, the first fully automated point-of-care technology for functional precision medicine will be developed using 3-dimensional patient-derived microtumors.
The ILT Institute for Lab Automation and Mechatronics is an institute of the OST – Eastern Switzerland University of Applied Sciences. The ILT provides expertise and applied research and development in the interdisciplinary field of automation and mechatronics. Its core competencies include laboratory automation, robotics, cyber-physical systems and medical engineering.
Read full press release.
Jens M. Kelm, CEO
info@precomb.com
ILT Media contact
Prof. Dr. Agathe Koller
agathe.koller@ost.ch
May
2021
PreComb Therapeutics appoints Dr. Patrick Griss as Strategic Advisor
Hombrechtikon, May 28th, 2021
PreComb Therapeutics today announced the addition of Dr. Patrick Griss, Executive Partner Zühlke Ventures AG, to the company’s strategic advisory board. The SAB will guide and advise the Company as it advances its novel and proprietary technology for functional precision medicine.
Patrick Griss is co-founder of Zühlke Ventures, the early-stage investment arm of the Zühlke Group. He is an active investor and board member in several technology companies and an expert for digital strategies and business models.
Read full press release.
Jens M. Kelm, CEO
info@precomb.com
Zühlke Media contact
Marius Gartmann
marius.gartmann@zuehlke.com
April
2021
PreComb Therapeutics AG secures CHF 2.2 Mio seed financing to advance personalized medicine for cancer patients
Hombrechtikon, April 26th, 2021
PreComb Therapeutics today announced the successful completion of the seed financing round led by Kinled Austria, the High-Tech Gründerfonds and FiveT Capital, in addition to participations from other investors. Patrick Aisher, managing partner at Kinled Austria, joined the company’s board of directors. The seed funding will help to advance the proprietary 3D3 Technology for patient-specific drug response analysis and position PreComb as a leader in point-of-care solutions to enable functional patient-specific drug testing directly in the clinic.
Read full press release.
PreComb Media contact
PreComb Therapeutics AG
Jens M. Kelm, CEO
info@precomb.com
HTGF Media Contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
Tel: +49-228-82300-188
s.grueter@htgf.de
HTGF Investor Contact
High-Tech Gründerfonds Management GmbH
Anke Caßing, Senior Investment Manager
Tel: +49-228-82300-148
a.cassing@htgf.de
2020
Oct
2020
Dr. Olivier Mauti joins PreComb as Chief Technology Officer
Hombrechtikon, October 1st, 2020
PreComb is very pleased to welcome Dr. Olivier Mauti to the leadership team as Chief Technology Officer. Olivier is a seasoned expert in laboratory automation, AI and data management and is joining the team to develop our fully automated drug profiling platform.
PreComb Media contact
PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com
2019
Oct
2019
NIH/NCATS and PreComb’s joint article published in SLAS Discovery
Hombrechtikon, October 29th, 2019
3D tumor models not only better reflect the spatial environment of the native tumor, but also allow information on efficacy and toxicity to be obtained in parallel from the same model. I would therefore like to thank my former InSphero team and the cooperation partners of NIH/NCATS and the Technical University of Aachen as well as Promega and Lonza for the successful development and publication of such an application for high throughput screening. For those interested, you can find the publication “A 3D Heterotypic Multicellular Tumor Spheroid Assay Platform to Discriminate Drug Effects on Stroma versus Cancer Cells” on the website of the following publisher: https://doi.org/10.1177/2472555219880194
PreComb Media contact
PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com
Jun
2019
PreComb joins the Society of Functional Precision Medicine
Hombrechtikon, June 28th, 2019
The Society for Functional Precision Medicine (Sf(PM)), chaired by Prof. Tony Letai of the Dana-Farber Cancer Institute, was established in recognition of the urgent need for matching cancer patients with the best personal therapy. The society aims to form a community to bring together scientists, physicians and companies leading the field of functional precision medicine. PreComb is joining the newly formed Society and is proud to be at the forefront of this new wave of personalized cancer treatment
Supplementary information:
Tony Letai has provided insights into genomic profiling in a enlightening podcast: Listen to Podcast
Feb
2019
NIH/NCATS and PreComb’s joint FEATURE article published in Drug Discovery Today
Wädenswil, February 11th, 2019
In times of exploding drug discovery and development costs 3D technologies to create ex vivo human tissues, organs, disease models and micro-physiological systems have the potential to reshape drug development. Together with the NIH/NCATS, PreComb has published a FEATURE article in in the January edition of “Drug Discovery Today” outlining what steps should be taken to exploit the 3D potential. A strategy is outlined for novel 3D-tailored holistic drug discovery concepts rather than piecemeal integration of 3D models into the current processes.
About NIH – NCATS
The National Center for Advancing Translational Sciences (NCATS) was established with the focus to transform the translational science process to enable faster delivery of new treatments for patients. It is one of 27 Institutes and Centers at the US National Institutes of Health (NIH).
PreComb Media contact
PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com
Jan
2019
PreComb funded bachelor thesis won Lab Science Award 2019
Wädenswil, January 29th, 2019
In recognition of her excellent bachelor thesis in the field of Life Sciences and Diagnostics, Toolpoint and the VHB Foundation awarded Ms. Dafina Ismaili with the Lab Science Award 2019. Her work on “Heterotypic multicellular tumor spheroids and their use in the evaluation of combination therapies” was funded by PreComb Therapeutics and conducted at the Centre for Cell Biology and Tissue Engineering at the University of Applied Sciences (ZHAW) in Wädenswil, Switzerland.
The award ceremony will take place at this year’s Swiss Symposium on Lab Automation at the University of Applied Sciences Rapperswil (HSR).
We congratulate Ms. Ismaili, the ZHAW Centre for Cell Biology and Tissue Engineering and the Group of 3D Tissues and Biofabrication for this success and the excellent collaboration.
Media contact
PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com
2018
Oct
2018
PreComb Therapeutics appoints Dr. Andrew Thomas as Strategic Advisor
Wädenswil, October 18th, 2018
PreComb, the leader in 3D microtumor combinatorial drug discovery, is excited to announce the appointment of Dr. Andrew Thomas as a new member of the Strategic Advisory Board. Dr. Thomas brings a wealth of expertise from over 20 year of key positions in global Pharma companies and small molecule drug discovery and development.
Dr. Thomas has previously been Global Head of Medicinal Chemistry at Roche, being responsible for creating and developing an innovative portfolio of small molecule medicines for Neuroscience, Ophthalmology, Rare Diseases, Inflammation, Infectious Diseases, Immunology and Oncology. He is a founder and executive partner of IPSO group, Investment Director at Helvetica Capital and an active driver of the Swiss Entrepreneurs Foundation.
“We are proud to welcome Andrew in our Advisory Board” said Jens Kelm, CEO of PreComb. “His wealth of pharma experience in drug discovery and development and his entrepreneurial thinking will add tremendous value to our company and our mission to deliver novel combination therapies for difficult to treat cancers.”
About PreComb Therapeutics
PreComb Therapeutics AG is a swiss-based biotechnology company focusing on the development of novel combination therapies, primarily for the use in oncology and immuno-oncology. PreComb is developing a phenotypical drug development platform using 3D microtumor cultures to enable high-throughput 3D combinatorial drug screening. The platform shall deliver more efficient cancer therapies to substantially improve long-term prognosis and quality-of-life for patients.
For more Information about PreComb Therapeutics, please visit https://www.precomb.com or follow us on LinkedIn.
Media contact
PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com
Sep
2018
PreComb announces the formation of the Strategic Advisory Board
Wädenswil, September 21st, 2018
PreComb, the leader in micro-tumor based drug discovery, today announced the formation of its new advisory board, a strategic committee of trusted advisors.
“The search for experienced Advisory Board members to support the development of PreComb has been a thoughtful exercise” said Jens M. Kelm, CEO of PreComb Therapeutics. “We’ve been very fortunate to attract highly networked advisors with extensive practical experiences in Biotech industry, preclinical and clinical cancer research. We are looking forward to work with our advisors to quickly implement our ideas and leverage their expertise to develop novel anti-cancer combination therapies.
Appointments of the Strategic advisory board include:
Dominik Escher, PhD – Founding partner of Puros Bioventures and former founder and CEO of ESBATech AG
Prof. Heinz Zwierzina, MD – Head of the Early Clinical Trial Unit within the Department for Haematology and Oncology at the University Hospital, Innsbruck
Prof. Laura Suter-Dick, PhD – Professor for Molecular Toxicology at the University of Applied Sciences Northwestern Switzerland (FHNW)
About PreComb Therapeutics
PreComb Therapeutics AG is a swiss-based biotechnology company focusing on the development of novel combination therapies, primarily for the use in oncology and immuno-oncology. PreComb is developing a phenotypical drug development platform using 3D microtissue culture to enable high-throughput combinatorial drug screening. The platform shall deliver more efficient cancer therapies to substantially improve long-term prognosis and quality-of-life for patients.
For more Information about PreComb Therapeutics, please visit https://www.precomb.com or follow us on LinkedIn.
Media contact
PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com